FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

• Status: Recruiting
• Trial end date: 2026-12-31

Summary

This prospective, randomized, controlled clinical study aims to evaluate the objective remission rate of FOLFOX hepatic artery infusion chemotherapy (HAI) in combination with systemic irinotecan with or without bevacizumab versus systemic intravenous FOLFOXIRI with or without bevacizumab in initially unresectable RAS-mutated colorectal cancer patients with liver metastases.

• Phase: Phase 2

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Anisodamine; Bevacizumab; Dexamethasone; Fluorouracil; Irinotecan; Leucovorin; Levoleucovorin; Oxaliplatin